Literature DB >> 8494749

IgE and its related phenomena in bullous pemphigoid.

H Soh1, H Hosokawa, Y Asada.   

Abstract

This study was designed to analyse IgE and its related phenomena in bullous pemphigoid (BP). We analysed 17 BP sera by indirect immunofluorescence (IIF) and immunoblotting (IB) using a monoclonal antibody to IgE. In addition, inflammatory cells in lesional skin from 11 patients with BP were analysed by the alkaline phosphatase-anti-alkaline phosphatase (APAAP) technique using monoclonal antibodies to IgE and Fc epsilon RII/CD23. IgE class anti-basement membrane zone (BMZ) autoantibody was detected in nine of 17 sera (52.9%) by IIF. IgG class anti-BMZ antibody could block the BMZ-binding reactivity of IgE class antibody. Titres of IgE class autoantibody in the sera ranged from 1:40 to 1:320, and statistically correlated with serum IgE levels. Two of 11 sera contained an IgE class autoantibody which recognized a 230-kDa BP antigen by IB. By radio-allergosorbent test (RAST), IgE-specific antibodies to an extended series of common inhalant and food allergens were detectable in six sera with high concentrations of total IgE (over 3,300 IU/ml). IgE-bearing and Fc epsilon RII-expressing cells were demonstrated in the upper dermis and along the BMZ in seven of 11 biopsy specimens by the APAAP technique. The distribution and number of IgE-bearing cells in the lesions were similar to those of the Fc epsilon RII-expressing cells. These results suggest that both IgE-mediated immune responses and autoimmunity characterize BP as distinctive features.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494749     DOI: 10.1111/j.1365-2133.1993.tb00193.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  6 in total

Review 1.  Bullous pemphigoid: from bench to bedside.

Authors:  Scott R A Walsh; David Hogg; P Régine Mydlarski
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Detection of serum IgE class anti-SSA antibodies in mothers with foetal loss.

Authors:  Iwao Sekigawa; Kazuhiko Kaneda; Hiroshi Kaneko; Yoshinari Takasaki; Kenji Takamori; Hideoki Ogawa
Journal:  Rheumatol Int       Date:  2007-12-19       Impact factor: 2.631

Review 3.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

4.  [Bullous pemphigoid: a new look at a well-known disease].

Authors:  G Balakirski; H F Merk; M Megahed
Journal:  Hautarzt       Date:  2014-12       Impact factor: 0.751

5.  IgE antibodies in sera from patients with bullous pemphigoid are autoantibodies preferentially directed against the 230-kDa epidermal antigen (BP230)

Authors:  R F Ghohestani; E Cozzani; E Delaporte; J F Nicolas; A Parodi; A Claudy
Journal:  J Clin Immunol       Date:  1998-05       Impact factor: 8.317

6.  High Index Values of Enzyme-Linked Immunosorbent Assay for BP180 at Baseline Predict Relapse in Patients With Bullous Pemphigoid.

Authors:  Hiroshi Koga; Kwesi Teye; Norito Ishii; Chika Ohata; Takekuni Nakama
Journal:  Front Med (Lausanne)       Date:  2018-05-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.